Rhythm Pharmaceuticals shares are trading higher after JMP Securities initiated coverage on the stock with a Market Outperform rating and announced a price target of $64.
Portfolio Pulse from Benzinga Newsdesk
Rhythm Pharmaceuticals shares rose following JMP Securities' initiation of coverage with a Market Outperform rating and a $64 price target.
September 17, 2024 | 4:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rhythm Pharmaceuticals shares increased after JMP Securities initiated coverage with a Market Outperform rating and set a price target of $64.
The initiation of coverage by JMP Securities with a positive rating and a high price target is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100